Skip to main content

Entrada Therapeutics, Inc.

For the period ended Sep 30, 2026. Filed Nov 5, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 5, 2026

TRDA$4.69-4.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

(In thousands, except share and per share amounts)

September 30,2026December 31,2025
Assets
Current assets:
Cash and cash equivalents$112,238$90,394
Marketable securities80,777205,304
Restricted cash, current portion—658
Collaboration receivable8381,177
Prepaid expenses and other current assets9,1018,719
Total current assets202,954306,252
Property and equipment, net5,2137,313
Restricted cash3,2923,292
Right-of-use assets, operating leases55,29860,451
Other non-current assets12370
Total assets$266,880$377,378
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable$4,865$2,289
Accrued expenses and other current liabilities16,27917,682
Operating lease obligations, current portion4,6214,138
Deferred revenue98342
Total current liabilities25,86324,451
Operating lease obligations, net of current portion42,69246,794
Total liabilities68,55571,245
Commitments and contingencies (Note 11)
Stockholders' equity:
Common stock, par value $0.0001; 150,000,000 shares authorized; 39,150,334 shares issued and outstanding as of September 30, 2026; and 38,284,221 shares issued and outstanding as of December 31, 202544
Additional paid‑in capital593,693578,571
Accumulated other comprehensive (loss) income(56)652
Accumulated deficit(395,316)(273,094)
Total stockholders' equity198,325306,133
Total liabilities and stockholders' equity$266,880$377,378
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.